¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"organic reaction type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • alcohol flush reaction
    ¾ËÄÚ¿ÃÈ«Á¶¹ÝÀÀ
  • alkaline reaction
    ¾ËÄ®¸®¹ÝÀÀ
  • allergic reaction
    ¾Ë·¹¸£±â¹ÝÀÀ
  • allograft reaction
    µ¿Á¾À̽ĹÝÀÀ
  • alternative reaction
    ±³´ë¹ÝÀÀ
  • anamnestic reaction
    ¸é¿ª±â¾ï¹ÝÀÀ
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, Ãʰú¹Î¹ÝÀÀ
  • anaphylactoid reaction
    À¯»ç¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, À¯»çÃʰú¹Î¹ÝÀÀ
  • bimolecular reaction
    À̺ÐÀÚ¹ÝÀÀ
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • biphasic reaction
    À̻󼺹ÝÀÀ
  • bisubstrate reaction
    µÎ±âÁú¹ÝÀÀ
  • biuret reaction
    ºä·¿¹ÝÀÀ
  • blanching reaction
    â¹é¹ÝÀÀ
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • adjustment reaction
    ÀûÀÀ¹ÝÀÀ
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • aerobic reaction
    È£±â¼º¹ÝÀÀ
  • affective reaction
    Á¤µ¿¹ÝÀÀ
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ
  • alarm reaction
    ¾Ë¸²¹ÝÀÀ
  • alcohol flush reaction
    ¾ËÄÚ¿ÃÈ«Á¶¹ÝÀÀ
  • alkaline reaction
    ¾ËÄ®¸®¹ÝÀÀ
  • allergic reaction
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • allograft reaction
    µ¿Á¾À̽ĹÝÀÀ
  • alternative reaction
    ±³´ë¹ÝÀÀ
  • anamnestic reaction
    ±â¿Õ¹ÝÀÀ
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, Ãʰú¹Î¹ÝÀÀ
  • anaphylactoid reaction
    À¯»ç¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, À¯»çÃʰú¹Î¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Prausnitz-K*stner (PK) reaction
    ÇÁ¶ó¿ì½º´ÏÃ÷-Ä¿½ºÆ®³Ê¹ÝÀÀ (PK¹ÝÀÀ, Á¦1Çü °ú¹Î¹ÝÀÀ Àü´Þ½Ã
  • Prausnitz-Kustner(P-K) reaction
    ÇÁ¶ó¿ì½º´ÏÃ÷ Äû½ºÆ®³Ê ¹ÝÀÀ
  • Quellung reaction
    Çù¸·ÆØÃ¢¹ÝÀÀ
  • Quellung reaction
    Çù¸·ÆØÃ¢½ÃÇè
  • Rivalta s reaction
    ¸®¹ßŸ¹ÝÀÀ.
  • Romers reaction
    ·Ú¸Ó¹ÝÀÀ (°áÇÙ±Õ°¨¿° ±â´ÏÇȹÝÀÀ, ÄÚÈ£Çö»ó°ú À¯»ç)
  • Sanarelli-Shwartzman reaction
    »ç³ª·¼¸®-½´¹ßÂ길¹ÝÀÀ
  • Schultz-Charton reaction = Schultz-Charton test
    ½¶Ã÷ Įư ¹ÝÀÀ
  • Schwartzmann reaction = Schwartzmann phenomenon
    ½´¹Ù¸£Ã÷¸¸ ¹ÝÀÀ
  • Wassermanns reaction
    ¹Ù¼¼¸£¸¸¹ÝÀÀ, ¸Åµ¶Ç÷û¹ÝÀÀ .
  • Weil Felix reaction
    ¿ÍÀÏ-Æç¸¯½º¹ÝÀÀ.
  • Weil Felix reaction
    ¹ÙÀÏ-Æç¸¯½º[¸®ÄÉÄ¡¾ÆÇ÷û]¹ÝÀÀ
  • Weil Felix reaction
    ¿ÍÀÏ-Æç¸¯½º¹ÝÀÀ.
  • Weil-Felix reaction
    ¿ÍÀÏ-Æç¸¯½º ¹ÝÀÀ
  • Widal reaction
    ºñ´Þ[ÀåÆ¼Çª½ºÇ÷û]¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • association type
    ¿¬»óÀ¯Çü
  • asthenia type
    ¹«·ÂüÇü.
  • atypical type
    ºñÁ¤Çü ÇüÅÂ
  • bell type
    Á¾¸ð¾ç, Á¾Çü.
  • blood group =b. type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood group =b. type
    Ç÷¾×Çü(úìäûû¡).
  • blood type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood type
    Ç÷¾×Çü(úìäûúþ)
  • body type
    üÇü
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
  • catatonic type
    ±äÀåÇü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • immune reaction
    ¸é¿ª ¹ÝÀÀ(Øóæ¹Úãëë)
  • irreversible reaction
    ºñ°¡¿ª ¹ÝÀÀ(ުʦæ½Úãëë)
  • Liebermann-Burchard reaction
    ¸®¹ö¸¸-¹öÄ«µå¹ÝÀÀ(Úãëë)
  • light reaction
    ±¤¹ÝÀÀ(ÎÃÚãëë)
  • Lohmann reaction
    ·Î¸Ç ¹ÝÀÀ(Úãëë)
  • Millard reaction
    ¹Ð¶óµå ¹ÝÀÀ(Úãëë)
  • Mannich reaction
    ¸¸´ÏÈ÷ ¹ÝÀÀ(Úãëë)
  • Mehler reaction
    ¸á·¯ ¹ÝÀÀ(Úãëë)
  • Millon reaction
    ¹Ì¿ë ¹ÝÀÀ(Úãëë)
  • mixed-order reaction
    È¥ÇÕ¼øÂ÷ ¹ÝÀÀ(ûèùêâ÷ó­Úãëë)
  • monomolecular reaction
    ´ÜºÐÀÚ¹ÝÀÀ(Ó¤ÝÂí­Úãëë)
  • ninhydrin reaction
    ´ÑÈ÷µå¸°¹ÝÀÀ(Úãëë)
  • nitroprusside reaction
    ³ªÀÌÆ®·ÎǪ·ç½Ãµå ¹ÝÀÀ(Úãëë)
  • nucleotide exchange reaction
    ´©Å¬¸®¿ÀŸÀÌµå ±³È¯¹ÝÀÀ(ÎßüµÚãëë)
  • opposing unidirectional reaction
    ¿ª ÀϹæÇâ¹ÝÀÀ(æ½ìéÛ°ú¾Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
OABP organic anion binding protein
OAD obstructive airway disease; organic anionic dye
OALF organic acid labile fluid
OASP organic acid soluble phosphorus
OBD organic brain disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CRT Choice Reaction Time
cPCR Competitive polymerase chain reaction
CFR Complement Fixation Reaction
CRT Continous reaction times
PCR DNA-polymerase chain reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • type cultural
    ´ëÇ¥ ±ÕÁ¾ ¹è¾ç, Ç¥ÁØ ¹è¾ç
  • type II
    2Çü
  • type III
    3Çü
  • type of eruption
    ¸ÍÃâÇü
  • type strain
    ´ëÇ¥ ±ÕÁ¾, Ç¥ÁØ ±ÕÁ¾
  • undulant type
    ÆÄ»óÇü
    ÆÄ»ó º¯µ¿À» Ư¡À¸·Î ÇÏ´Â Çü.
  • water in oil type
    À¯Áß¼öÀûÇü
  • Widman type flap
    WidmanÇü ÇÇÆÇ
  • wild type
    ¾ß»ýÇü
  • XY-type
    ¿¢½º¿ÍÀÌ Çü
    ¾Ï¼ö ¾î´À ÇÑÂÊÀÇ ¼º ¿°»öü Áß 1°³°¡ ´Ù¸¥ ¼º ¿°»öü¿Í Çü»óÀ» ´Þ¸®ÇÏ´Â »óÅ·μ­ ¼ºÀÌ °áÁ¤µÇ´Â °ÍÀ¸·Î, ÀÌ »ý¹°À» XY ÇüÀÇ »ý¹°À̶ó°í Çϸç, ¼öÄÆÀÌ ÀÌÇüÀÎ XYÇü , ¾ÏÄÆÀÌ ÀÌÇüÀÎ ZWÇüÀ¸·Î ±¸º°Çϱ⵵ ÇÑ´Ù.
  • Abderhalden's reaction
    ¾Ðµ¥¸£ÇÒµ§ ¹ÝÀÀ
    ÀÌÁ¾ ´Ü¹éÁúÀÌ Ç÷¾× Áß¿¡ ħÀÔÇϸé, »ýü´Â À̰ÍÀ» ºÐÇØÇÏ´Â È¿¼Ò¸¦ »ý»êÇÔÀ¸·Î½á ÀÀ´äÇÑ´Ù´Â ±¸ °¡¼³¿¡ ±âÃÊÇÑ Ç÷û ¹ÝÀÀÀÌ´Ù. ÀÌ·¯ÇÑ ¹æ¾î È¿¼Ò´Â
  • accelerated reaction
    ÃËÁø ¹ÝÀÀ, °¡¼Ó ¹ÝÀÀ
    º¸Åë ¶§º¸´Ù ´Ü ½Ã°£ ³»¿¡ ÀϾ´Â ¹ÝÀÀ.
  • acute hemolytic transfusion reaction
    ±Þ¼º ¿ëÇ÷¼º ¼öÇ÷ ¹ÝÀÀ
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute situational stress reaction
    ±Þ¼º »óȲ¼º ½ºÆ®·¹½º ¹ÝÀÀ
    ±ØµµÀÇ È¯°æÀû ½ºÆ®·¹½º¿¡ ´ëÇÑ ÀϽÃÀûÀÎ ¹ÝÀÀÀ¸·Î ±âÃÊÀûÀÎ Á¤½Å Àå¾Ö°¡ ¾ø´Â °³Àο¡°Ô ³ªÅ¸³­´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple lipoprotein-type hyperlipidaemia <biochemistry> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides. There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease.
Origin: Gr. Haima = blood
(27 Sep 1997)
contact-type dermatitis Dermatitis resembling contact dermatitis or eczema, but caused by an ingested or injected allergen, usually a drug, and with a widespread or generalised distribution.
(05 Mar 2000)
Cowdry's type A inclusion bodies Droplet-like masses of acidophilic material surrounded by clear halos within nuclei, with margination of chromatin on the nuclear membrane.
(05 Mar 2000)
Cowdry's type B inclusion bodies Droplet-like masses of acidophilic material surrounded by clear halos within nuclei, without other nuclear changes during early stages of development of the inclusion.
(05 Mar 2000)
habitat type <ecology> A land or aquatic unit, consisting of an aggregation of habitats having equivalent structure, function, and responses to disturbance.
(09 Oct 1997)
haemadsorption virus type 1 parainfluenza virus type 3
haemadsorption virus type 2 parainfluenza virus type 1
C type lectin <cell biology> One of two classes of lectin produced by animal cells, the other being the S type.
The C type lectins require disulphide linked cysteines and Ca ions in order to bind to a specific carbohydrate (c.f. S type lectins). The carbohydrate recognition domain of C type lectins consists of about 130 amino acids which contains 18 invariant residues in a highly conserved pattern.
These invariant residues include cysteines which probably form disulphide bonds. So far, all identified C type lectins are extracellular proteins and include both Integral membrane proteins, such as the asialoglycoprotein receptor and soluble proteins.
(06 Aug 1998)
C type virus <molecular biology, virology> Originally C type particles identified in mouse tumour tissue and later shown to be oncogenic RNA viruses Oncovirinae) that bud from the plasma membrane of the host cell starting as a characteristic electron dense crescent.
Include feline leukaemia virus, murine leukaemia and sarcoma viruses.
(18 Nov 1997)
haemophilus influenzae type b The majority of type b isolates are from biotype I. The organism can cause life-threatening meningitis, primarily in children 6-12 months of age. Children with underlying disease or immunodeficiency are also at high risk for infection. A vaccine is available and recommended for children under 5 years of age.
(12 Dec 1998)
haemophilus influenzae type b immunization See HIB immunization,
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á